A tissue microarray study of osteosarcoma: Histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 5, 2010, Pages 453-461

  Mayordomo, Empar ^a   MacHado, Isidro ^a   Giner, Francisco ^a   Kresse, Stine H ^b   Myklebost, Ola ^b   Carda, Carmen ^a   Navarro, Samuel ^a   Llombart Bosch, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

immunohistochemical; osteosarcomas; TMAs; xenografts

Indexed keywords

CAVEOLIN 1; CD99 ANTIGEN; CYTOKERATIN; KI 67 ANTIGEN; OSTEOCALCIN; OSTEONECTIN; PARAFFIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; PROTEIN S 100; SURVIVIN; TRANSCRIPTION FACTOR SOX9; TUMOR MARKER;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA; WORLD HEALTH ORGANIZATION; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEASIBILITY STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICROARRAY ANALYSIS; OSTEOCALCIN; OSTEONECTIN; OSTEOSARCOMA; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957554389     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181daace3     Document Type: Article

References (38)

1. Fletcher CDM, Krishnan UK, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bones. World Health Organization Classification of Tumours. 2002.
2. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007; 2: 6.
3. Wittig JC, Bickels J, Priebat D., et al. Osteosarcoma: a multi-disciplinary approach to diagnosis and treatment. Am Fam Physician. 2002; 65: 1123-1132.
4. Sailor J, McCarthy EF, Weber K.L., et al. Low-grade intramedullary osteosarcoma of the tibia presenting as an intracortical lesion. Orthopedics. 2008; 31: 714.
5. Hauben EI, Weeden S, Pringle J., et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002; 38: 1218-1225.
6. Shehadeh AM, Haiba MA, Henshaw R.M., et al. Telangiectatic osteosarcoma of the patella. Orthopedics. 2008; 31: 808.
7. Devaney K, Vinh TN, Sweet DE Small cell osteosarcoma of bone: an immunohistochemical study with differential diagnostic considerations. Hum Pathol. 1993; 24: 1211-1225.
8. Fanburg JC, Rosenberg AE, Weaver D.L., et al. Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma. Am J Clin Pathol. 1997; 108: 464-473.
9. Chano T, Matsumoto K, Ishizawa M., et al. Analysis of the presence of osteocalcin, S-100 protein, and proliferating cell nuclear antigen in cells of various types of osteosarcomas. Eur J Histochem. 1996; 40: 189-198.
10. Fanburg-Smith J.C., Bratthauer GL, Miettinen M. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases. Hum Pathol. 1999; 30: 32-38.
11. Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009; 4: 12-26.
12. Wang LL. Biology of osteogenic sarcoma. Cancer J. 2005; 11: 294-305.
13. Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res. 2008; 466: 2114-2130.
14. Maitra A, Roberts H, Weinberg A.G., et al. Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosar-comas. Int J Cancer. 2001; 95: 34-38.
15. Benassi MS, Molendini L, Gamberi G., et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 1999; 84: 489-493.
16. Benassi MS, Molendini L, Gamberi G., et al. Altered G1 phase regulation in osteosarcoma. Int J Cancer. 1997; 74: 518-522.
17. Pellin A, Boix-Ferrero J, Carpio D., et al. Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol. 1997; 6: 333-341.
18. Walkley CR, Qudsi R, Sankaran V.G., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008; 22: 1662-1676.
19. Cantiani L, Manara MC, Zucchini C, et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res. 2007; 67: 7675-7685.
20. Llombart-Bosch A., Carda C, Boix J., et al. Value of nude mice xenografts in the expression of cell heterogeneity of human sarcomas of bone and soft tissue. Pathol Res Pract. 1988; 183: 683-692.
21. Bruheim S, Bruland OS, Breistol K, et al. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res. 2004; 10: 133-141.
22. Dass CR, Ek ET, Choong PF Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol. 2007; 133: 193-198.
23. Packeisen J, Korsching E, Herbst H., et al. Demystified⋯tissue microarray technology. Mol Pathol. 2003; 56: 198-204.
24. Machado I, Giner F, Mayordomo E., et al. Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochem-istry and xenograft study. Diagn Pathol. 2008; 3(SUPPL. 1): S25.
25. Petrov SV, Machado I, Boulytcheva I.V., et al. New approaches in the diagnosis of small-cell round tumors of bone and soft tissue. Arkh Patol. 2009; 71: 34-40.
26. Subramaniam MM, Navarro S, Pellin A., et al. Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants. Virchows Arch. 2006; 449: 435-447.
27. Somers GR, Ho M, Zielenska M., et al. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol. 2005; 8: 525-532.
28. Nilbert M, Engellau J. Experiences from tissue microarray in soft tissue sarcomas. Acta Orthop Scand Suppl. 2004; 75: 29-34. (Pubitemid 38580811)
29. Tokunaga K, Ogose A, Endo N., et al. Human osteosarcoma (OST) induces mouse reactive bone formation in xenograft system. Bone. 1996; 19: 447-454.
30. Hara A, Ikeda T, Nomura S., et al. In vivo implantation of human osteosarcoma cells in nude mice induces bones with human-derived osteoblasts and mouse-derived osteocytes. Lab Invest. 1996; 75: 707-717.
31. Nakajima H, Sim FH, Bond J.R., et al. Small cell osteosarcoma of bone. Review of 72 cases. Cancer. 1997; 79: 2095-2106.
32. Devoe K, Weidner N. Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol. 2000; 17: 216-224.
33. Hasegawa T, Hirose T, Seki K., et al. Histological and immuno-histochemical diversities, and proliferative activity and grading in osteosarcomas. Cancer Detect Prev. 1997; 21: 280-287.
34. Okada K, Hasegawa T, Yokoyama R., et al. Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol. 2003; 56: 742-746.
35. Hasegawa T, Hirose T, Kudo E., et al. Immunophenotypic heterogeneity in osteosarcomas. Hum Pathol. 1991; 22: 583-590.
36. Trieb K, Lehner R, Stulnig T., et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003; 29: 379-382.
37. Osaka E, Suzuki T, Osaka S., et al. Survivin as a prognostic factor for osteosarcoma patients. Acta Histochem Cytochem. 2006; 39: 95-100.
38. Jong R, Davis AM, Mendes M.G., et al. Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases. Sarcoma. 2000; 4: 47-55.